louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03029923: Integrated Smoking Cessation and Mood Management for ACS Patients
Official title: Integrated Smoking Cessation and Mood Management for ACS Patients (PACES Phase IV Vanguard R56 Trial)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Acute Coronary Syndrome
Tobacco Use
Keywords: smoking
depression
Behavioral Activation
Lead sponsor: The Miriam Hospital
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2017-01-24
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Quitting smoking following acute coronary syndrome can reduce mortality up to 50%. However, depression and smoking are highly co-morbid and depressed mood may interfere with cessation and independently predicts mortality. Thus, a single, integrated treatment for both smoking and depression could be highly effective in reducing post-acute coronary syndrome mortality. Behavioral Activation (BA) is a well established treatment for depression and has recently shown promise as a treatment for smoking cessation. The investigators systematically developed an intervention integrating gold standard smoking cessation counseling with existing BA based mood management techniques for post-ACS smokers; Behavioral Activation Treatment for Cardiac Smokers (BAT-CS).

Objective: For this R56 the investigators will conduct a vanguard trial to pilot all methods, materials, and systems for the later fully powered BAT-CS vs. attention control trial. The investigators will enroll up to 36 smokers with ACS and randomize them to 12 weeks of BAT-CS or an attention control (Health and Wellness Education). Both groups will be offered the nicotine patch if medically safe.


Eligibility criteria: Inclusion Criteria:

1. hospital inpatients with an ACS diagnosis documented in medical record,
2. smoked 1 or more cigarettes per day before being hospitalized,
3. age of 18-75,
4. English fluency,
5. lives within a 1 hour drive of the admitting hospital and has no plans to move away from the area for 1 year,
6. willing to consider quitting smoking at discharge,
7. has telephone, and
8. willing to consent to all study procedures.

Exclusion Criteria:

1. limited mental competency (i.e., Mini Mental Status Exam score ≤ 23);
2. presence of severe mental illness that would interfere with participation (e.g., schizophrenia) or suicidality;
3. expected discharge to hospice; and
4. currently attending counseling for depression or smoking cessation.

Primary outcomes:
measure: Treatment Acceptability
timeFrame: 12 weeks post-Discharge
Secondary outcomes:
measure: Smoking Cessation
timeFrame: 12 weeks post-Discharge
measure: Depression Symptoms
timeFrame: 12 weeks post-Discharge
Other outcomes:
Locations:
city: Providence
country: United States
facility: The Miriam Hospital
state: Rhode Island
Study officials:
References:
Clinical trial NCT03052023: Comparative Study Between Lap. Dual Approach, Lap. Trans Abdominal Pre-peritoneal and Lichtenstein Procedures
Official title: Inguinal Hernioplasty: Comparative Study Between Laparoscopic Dual Approach, Laparoscopic Trans Abdominal Preperitoneal and Lichtenstein Procedures. A Prospective Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Inguinal Hernioplasty
Keywords: dual approach
laparoscopic hernioplasty
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-02-14
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: comparative study between three procedures of inguinal hernioplasty; open (LICHTENSTEIN), TAPP, and laparoscopic DUAL APPROACH (modified TAPP)
Primary purpose: TREATMENT

Brief summary: This study designed to compare the new laparoscopic dual approach to inguinal hernia repair with trans-abdominal preperitoneal (TAPP) and lichtenstein repair (open procedure)

Detailed description: inguinal hernioplasty is a procedures where synthetic mesh is used to strengthen the inguinal tissues sites for hernia repair different methods used which is either anterior approach (open Lichtenstein) or laparoscopic posterior approach through the abdomen (TAPP) comparing these two methods by new approach which is considered to some extent a modified TAPP by pneumo-dissection of pre-peritoneal space with abdominal approach by lap. repair

Eligibility criteria: Inclusion Criteria:

* Adult male patient (older than 18y).
* Not complicated.
* No previous lower abdominal incisions (lower abdominal midline and lower paramedian incision in the same side of hernia).
* No contraindication for general anesthesia.
* Not recurrent.

Exclusion Criteria:

* any one not in fulfill inclusion criteria

Primary outcomes:
measure: operative time
timeFrame: from the inflation of the abdomen till deflation and port closure ---for lichtenstein from skin incision to skin closure.
Secondary outcomes:
measure: intraoperative injuries
timeFrame: intra operative
measure: intra operative bleeding
timeFrame: intraoperative
measure: post operative pain
timeFrame: immediately post operative and 6 ,12, 24 hours and two weeks post operative
measure: post operative wound complication
timeFrame: 2 weeks post operative ,3 ,6 and 12 months postoperative
measure: post operative chronic pain
timeFrame: follow up at 3 months , 6 months and one year for pain assessment by VAS
measure: recurrence
timeFrame: 3 months, 6 months and one year
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut university hospital
Study officials:
affiliation: Assiut university hospital faculty of medicine
name: mostafa A. hamad, professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Nasr MM. Early results of dual approach hernioplasty (DAH): an innovative laparoscopic inguinal hernioplasty technique. Surg Endosc. 2016 Mar;30(3):1113-8. doi: 10.1007/s00464-015-4308-5. Epub 2015 Jun 23.
Clinical trial NCT04290923: Determination of Blood Tumor Cells
Official title: Determination of Blood Tumor Cells Using Magnetic Nanoparticles
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Abnormalities Cell Epithelial
Keywords: Epithelial Cell Adhesion Molecule
Magnetite Nanoparticles
Tumor cells
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2020-03-02
Enrollment: 71
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Criterion for the enrollment is the presence of an epithelial cell carcinoma or the presence of a non-solid tumor (i.e. lymphoma or leucemia)

Brief summary: Magnetic nanoparticles coated with anti-EpCAM or anti-CD52 antibodies will be tested ex-vivo in patients blood .

Detailed description: Magnetic nanoparticles, coated with epithelial cell adhesion molecule (EpCAM)-antibodies are designed to interact with epithelial tumor cells. Aim of this study is to see if circulating tumor cells (EpCAM as marker)can be removed out of the blood with the help of these particles. Patients suffering from prostate, colon, lung or pancreatic cancer will be asked to test their blood.

Similarly, magnetic nanoparticles will be coated with antibodies, directed against non-solid tumors in the blood such as lymphoma or leukemia (CD52 as marker).

Eligibility criteria: Inclusion Criteria:

Epithelial cell cancer, advanced stage Non-solid tumors (lymphoma, leukemia)

Exclusion Criteria:

Inability to understand the language of the center (German)

Primary outcomes:
measure: Number of CTC / lymphocytes removed
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich
Study officials:
affiliation: University of Zurich
name: Beatrice H Beck Schimmer, Prof
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug 19;351(8):781-91. doi: 10.1056/NEJMoa040766.
citation: Herrmann IK, Bernabei RE, Urner M, Grass RN, Beck-Schimmer B, Stark WJ. Device for continuous extracorporeal blood purification using target-specific metal nanomagnets. Nephrol Dial Transplant. 2011 Sep;26(9):2948-54. doi: 10.1093/ndt/gfq846. Epub 2011 Feb 10.
citation: Herrmann IK, Schlegel A, Graf R, Schumacher CM, Senn N, Hasler M, Gschwind S, Hirt AM, Gunther D, Clavien PA, Stark WJ, Beck-Schimmer B. Nanomagnet-based removal of lead and digoxin from living rats. Nanoscale. 2013 Sep 21;5(18):8718-23. doi: 10.1039/c3nr02468g.
Clinical trial NCT00557323: Long-term Effect of Lanthanum Carbonate on Bone
Official title: A Long-term, Observational Study to Monitor Mortality, Bone-related Adverse Events and the Safety of Subjects Who Were Recruited Into Study SPD405-309
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hyperphosphatemia
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2007-11-14
Enrollment: 34
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any patients from study SPD405-309 who were exposed to lanthanum carbonate

Brief summary: Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse events or other serious adverse events, as well as the collection of mortality data.


Eligibility criteria: Inclusion Criteria:

* Any patient who had exposure to lanthanum carbonate in SPD405-309

Primary outcomes:
measure: Number of Study-emergent Bone-related Adverse Events (AEs)
timeFrame: 5 years
Secondary outcomes:
measure: Number of Study-emergent Deaths
timeFrame: 5 years
Other outcomes:
Locations:
city: Lynwood
country: United States
facility: Imperial care Dialysis Center
state: California
city: Torrance
country: United States
facility: Barnett Research and Communications Medical Group
state: California
city: Springfield
country: United States
facility: Western new England Renal & Transplant Associates
state: Massachusetts
city: Canton
country: United States
facility: Mercy Medical Center
state: Ohio
city: Providence
country: United States
facility: Hypertension & Nephrology, Inc.
state: Rhode Island
city: Nashville
country: United States
facility: Nephrology Associates, PC
state: Tennessee
city: Burlington
country: United States
facility: University of Vermont
state: Vermont
city: Richmond
country: United States
facility: Nephrology Associates, PC
state: Virginia
city: Bad Konig
country: Germany
state: HE
city: Aachen
country: Germany
facility: KfH Zentrum
city: Bad Homburg
country: Germany
facility: Dialysenzentrum
city: Berlin
country: Germany
facility: KfH Kuratorium duer Dialyse und Nierentransplanta Dialysezentrum Moabit
city: Berlin
country: Germany
facility: KfH Dialysezentrum
city: Hamburg
country: Germany
facility: Dialysezentrum Barmbek
city: Hamburg
country: Germany
facility: Dialysepraxis Altona
city: Rosenheim
country: Germany
facility: KfH Dialysezentrum
city: Cambridge
country: United Kingdom
facility: Addenbrooke's Hospital
city: Carshalton
country: United Kingdom
facility: St. Helier Hospital
city: Manchester
country: United Kingdom
facility: Manchester Royal Infirmary
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT05155423: A Prospective Study of Performing MRI Simulation in Treatment Position in Spinal Stereotactic Body Radiation Therapy
Official title: A Prospective Study of Performing MRI Simulation in Treatment Position in Spinal Stereotactic Body Radiation Therapy
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Spinal Metastases
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: Elekta Limited
First posted: 2021-12-13
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: MDACC Cancer Participants

Brief summary: To learn the usefulness of performing MRI scans in different positions and learn the best practice for spinal stereotactic body radiation therapy (spinal SBRT) planning and dose delivery.

Detailed description: 1. Objectives

1. Assess the feasibility of performing MRI scans in the treatment position for accurate treatment planning and dose delivery in spinal stereotactic body radiation therapy (spinal SBRT).
2. Characterize the improved accuracy of image fusion between MRI and CT and its dosimetric impact when performing MRI scans in treatment position in spinal SBRT.
3. Assess the ability of MRI simulation to accurately target extended spinal targets beyond the current targeting limitations (\>3 consecutive vertebral body levels)
4. Optimize the workflow of using MRI simulation in treatment planning and dose delivery.

Eligibility criteria: 3.1. Inclusion Criteria

1. Greater than or equal to 18 years of age
2. Pathologically confirmed diagnosis of cancer, including, but not limited to non-small cell lung cancer, breast, prostate, renal cell, melanoma, gastrointestinal, sarcoma, thyroid, head and neck primary, and carcinoma of unknown primary
3. Signed informed consent
4. Willing to undergo 2 MRI simulations in one or multiple sessions, one with immobilization device, and the other without.
5. Patients undergoing spinal SBRT 3.2. Exclusion Criteria

a. Patient with a relative or absolute contraindication to MRI (such as pacemaker, etc.) b. Patients with significant instrumentation or cement at the site of interest causing artifact c. Inability to tolerate with immobilization device for greater than 30 minutes

Primary outcomes:
measure: Performing MRI scans in the treatment position for accurate treatment planning.
timeFrame: through study completion, an average of 1 year
measure: Performing MRI scans in the treatment position for dose delivery in spinal stereotactic body radiation therapy (spinal SBRT).
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Amol Ghia, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00015223: Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5
Official title: Methyphendidate in the Treatment of Cocaine Dependent Patients With Adult ADHD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cocaine-Related Disorders
Substance-Related Disorders
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: Cincinnati MDRU
First posted: 2001-04-18
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is the use of Methylphenidate in the treatment of cocaine dependence and Attention Deficit Hyperactivity Disorder (ADHD) comorbidity.

Detailed description: The objective of this study is to determine the safety and efficacy of methylphenidate in a population of patients who are cocaine dependent and suffer from attention deficit hyperactivity disorder.

Eligibility criteria: Inclusion Criteria:

Cocaine-dependent. Meets the DSM-IV criteria for ADHD. Actively using cocaine within the past 30 days of screening.

Exclusion Criteria:

Symptoms of AIDS. Significant medical disorder. DSM-IV criteria for any substance other than cocaine, alcohol, nicotine, marijuana, caffeine. Requires detoxification from ETOH or benzos. History of seizures.

Primary outcomes:
measure: Cocaine use
measure: Methylphenidate retention
measure: Safety assessments
measure: Psychosocial counseling sessions
Secondary outcomes:
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: Cincinnati MDRU
state: Ohio
Study officials:
affiliation: U of Cincinnati
name: Gene Somoza, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04355923: Confinement and Spondyloarthritis Treatment
Official title: Impact of Confinement on the Treatment of Spondyloarthritis.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Spondyloarthritis
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2020-04-21
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with spondyloarthritis and member of ACS patient association group

Brief summary: Evaluate the impact of confinement on treatment use in spondyloarthritis. Study hypothesis that with the confinement, subjects will stop their treatment. The main objective is to study the impact of confinement on treatment. And secondly to look for for specific psychological profile linked to the interruption of the treatment. the study population consists of patients with spondyloarthritis and belonging to a patient association (ACS). All patients over 18 are included. A mailing questionnaire will be send to all patients. data on diseases activity and treatment will be collected


Eligibility criteria: Inclusion Criteria:

* spondyloarthritis,
* age over 18 ans
* treatment by NSAID or biological treatment to be part of the patient association "ACS" (action contre les spondylarthropathies).

Primary outcomes:
measure: treatment use
timeFrame: 1 month
Secondary outcomes:
measure: activity of disease
timeFrame: 1 week
measure: psychological aspects
timeFrame: 1 month
measure: psychological aspects
timeFrame: 1 month
Other outcomes:
Locations:
city: Nice
country: France
facility: CHU de Nice
Study officials:
References:
Clinical trial NCT01588223: Non Invasive Diagnostic of Endometrial Receptivity
Official title: A Non Invasive Diagnostic of Endometrial Receptivity Based on Lipidomic Profile on Endometrial Fluid.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endometrial Receptivity Failure
Lead sponsor: Igenomix
Sponsor class: INDUSTRY
First posted: 2012-04-30
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to determine a lipidomic profile on the endometrial fluid, that can predict endometrial receptivity.


Eligibility criteria: Inclusion Criteria:

* Oocyte donors undergoing controlled ovarian stimulation
* Regular menstrual cycles
* no abnormal karyotype
* generally healthy
* BMI 19-29 Kg/m2 (both inclusive)
* 18 to 35 years old.

Exclusion criteria:

-patients diagnosed with endometriosis and/or endometritis.

Primary outcomes:
measure: Levels of lipids in the endometrial fluid as a diagnostic factor.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: IVI Valencia
Study officials:
References:
Clinical trial NCT06738823: Effect of Wii Fit Training in Comparison to Vestibular Rehabilitation Training on Balance in Patients With Benign Paroxysmal Postional Vertigo
Official title: Effect of Wii Fit Training in Comparison to Vestibular Rehabilitation Training on Balance in Patients With Benign Paroxysmal Postional Vertigo
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Benign Paroxysmal Positional Vertigo
Balance
Vertigo
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2024-12-18
Enrollment: 38
Sex: ALL
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: THIS STUDY IS A RANDOMIZED CONTROL TRIAL AND THE PURPOSE OF THE STUDY IS TO DETERMINE THE EFFECT OF WIIFIT TRAINING IN COMPARISON TO VESTIBULAR REHAB TRAINING ON BALANCE IN PATIENTS WITH BENIGN PAROXYSMAL POSITIONAL VERTIGO

Detailed description: Effects of wiifit training will be assessed for balance and vertigo which includes the parameters of balance training.

Benign Paroxysmal Positional Vertigo patients aged 30-60 years The participants will be assessed through Vestibular Rehabilitation questionnaire (VRBQ), Dizziness handicap inventory (DHI), Functional reach test, Clinical test for sensory integration in balance and vertigo symptom scale.

Informed consent will be taken after which the participants will be recruited into two groups, where one group will receive wiifit training and other group will receive vestibular rehabilitation training.

Base-line and post-treatment measurement will be taken for analysis.

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with benign paroxysmal positional vertigo.
* Aged 30-60 years.
* Ability to stand and walk independently.
* Male and Female
* Positive Dix Hallpike Test
* DHI Scale: 36-42 (moderate Handicap)

Exclusion Criteria:

* patients with history of vestibular surgery or cochlear implantation.
* Patients with history of seizures or epilepsy.
* patients with a pacemaker or implantable cardioverter-defibrillator(ICD).
* Patients with history of severe head injury or concussion within the past year.
* No other vestibular disorders or conditions that may affect balance.

Primary outcomes:
measure: Static Balance
timeFrame: 6 weeks
measure: Vertigo
timeFrame: 6 weeks
measure: Static Balance
timeFrame: 6 weeks
measure: Dynamic balance
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Foundation University College of Physical Therapy
Study officials:
References: